New data reinforce rosnilimab’s efficacy profile in rheumatoid arthritis (RA) with deepening of clinical responses, including CDAI remission, ...

A study presented at ACR Convergence 2025 suggests that GLP 1 receptor agonists reduce flares and systemic inflammation in ...

The new biotech Elevara plans to initiate Phase II testing of its lead candidate ELV001 as an add-on treatment for rheumatoid ...

Still, it remains possible that preventing (or even delaying) difficult-to-treat RA could tip that balance, if patients can ...

New research presented at ACR 2025 shows GLP-1 receptor agonists, used for diabetes and obesity, may reduce rheumatoid ...

XBiotech Inc. (($XBIT)) announced an update on their ongoing clinical study. Study Overview: XBiotech Inc. is conducting a Phase II, double-blind, ...

Investing.com -- AnaptysBio Inc (NASDAQ:ANAB) stock rose 4.4% on Wednesday after the clinical-stage biotech company announced positive late-breaking data from its Phase 2b trial of rosnilimab in ...

A neck implant designed to treat rheumatoid arthritis provides automatic therapy that lasts one minute per day.

Dr. Beth Jonas answers the question: 'Anti-TNF Meds For Rheumatoid Arthritis?' — -- Question: What are anti-tumor necrosis factor (anti-TNF) medications and how are they used to treat rheumatoid ...

Inflammatory arthritis resulting from immune checkpoint inhibitor use is immunologically unique and likely driven by T cells ...

RA may increase the likelihood of experiencing diarrhea due to medication side effects, the presence of other autoimmune conditions, or complications like rheumatoid vasculitis and AA amyloidosis. Gut ...

New data reinforce rosnilimab’s efficacy profile in rheumatoid arthritis (RA) with deepening of clinical responses, including CDAI remission, from Week 12 to Week 28 regardless of prior advanced ...